Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results ...

Serena Williams is opening up about her fitness journey, revealing that she uses the injectable GLP-1 weight loss drug ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a leading treatment in the fields of diabetes and obesity, with recent preclinical and clinical studies indicating significant ...

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted predominantly by intestinal enteroendocrine L cells in response to nutrient ingestion. By enhancing insulin secretion, delaying ...

Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have ...

Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs ...

(HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov. 14 ...

About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident ...

The intricate interplay between pancreatic beta cells and glucagon-like peptide-1 (GLP-1) has drawn considerable attention in efforts to improve the diagnosis and treatment of diabetes and ...

According to published results, glucagon-like peptide-1 agonists may not be associated with increased complications for patients with diabetes who undergo total hip arthroplasty.Results showed ...